206181-90-0

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloropyridine-2-carboxaldehyde serves as an essential intermediate in the synthesis of pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Chloropyridine-2-carboxaldehyde is utilized as an intermediate for the production of various agrochemicals. Its involvement in this industry is vital for the creation of effective solutions for agricultural applications.
Used in Dye and Pigment Production:
3-Chloropyridine-2-carboxaldehyde is also employed in the manufacturing of dyes and pigments, where its chemical properties are harnessed to produce a range of colorants used in different industries.
Used in Fine Chemicals Synthesis:
3-Chloropyridine-2-carboxaldehyde is a valuable intermediate for the synthesis of other fine chemicals, highlighting its importance in the chemical industry for creating specialty products with specific applications.
Safety Note:
Given its classification as a hazardous material, 3-Chloropyridine-2-carboxaldehyde requires careful handling to prevent irritation to the skin, eyes, and respiratory system. Proper safety measures should be implemented during its use to ensure the well-being of individuals in contact with 3-Chloropyridine-2-carboxaldehyde.

InChI:InChI=1/C6H4ClNO/c7-5-2-1-3-8-6(5)4-9/h1-4H

Upstream product

• 60588-81-0 3-chloro-2-hydroxy-methyl-pyridine 
• 57266-69-0 3-chloropyridine-2-carboxylic acid 
• 626-60-8 3-Chloropyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 204569-87-9 3-chloro-2-vinylpyridine 
• 96424-68-9 2-bromo-3-chloropyridine 
• 24721-92-4 1-Dimethylamino-ethanol 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 7757-82-6 sodium sulfate 
• 72093-03-9 3-chloro-2-methylpyridine 

Downstream Products

• 17288-32-3 1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis method of (R)-3-chloropyridyl-2-trifluoroethylamine hydrochloride

The invention discloses a synthesis method of (R)-3-chloropyridyl-2-trifluoroethylamine hydrochloride, and the synthesis method is characterized in that a Grignard reaction, a chiral induction addition reaction and a deprotection reaction are sequentially carried out to finally prepare a finished product. The invention provides a brand-new synthesis method of the (R)-3-chloropyridyl-2-trifluoroethylamine hydrochloride for the first time. The synthetic method is short in route, raw materials are easy to obtain, operation is easy, a continuous flow microreactor technology is adopted in the first step, reactants are rapidly and effectively mixed, the reaction time and the reaction temperature are accurately controlled, side reactions are avoided, and the conversion rate and safety are effectively improved. The compound 4 with high chiral purity is obtained through chiral induction addition reaction and recrystallization purification, and the de value of the compound 4 is greater than 99.5%. The post-treatment method is simple in post-treatment operation, column chromatography treatment is not needed after each step of reaction, reactants can be purified only through washing and extraction of a solvent, and the method is a novel post-treatment purification method.

BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF

The invention provides novel compounds having the general formula (I): (I) wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

METHOD FOR PRODUCING BENZOXAZOLE COMPOUND

PROBLEM TO BE SOLVED: To provide a new method for producing a benzoxazole compound represented by formula (1) (R is a chain hydrocarbon group; n is 0-3; X is a halogen atom, -SR1 or -S(O)2R1; R1 is a chain hydrocarbon group or the like). SOLUTION: The benzoxazole compound is obtained through the reaction of a compound represented by formula (2) and formula (3) in the presence of oxidizing agent. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Continuous flow magnesiation of functionalized heterocycles and acrylates with TMPMgCl·LiCl

A flow procedure for the metalation of functionalized heterocycles (pyridines, pyrimidines, thiophenes, and thiazoles) and various acrylates using the strong, non-nucleophilic base TMPMgCl·LiCl is reported. The flow conditions allow the magnesiations to be performed under more convenient conditions than the comparable batch reactions, which often require cryogenic temperatures and long reaction times. Moreover, the flow reactions are directly scalable without further optimization. Metalation under flow conditions also allows magnesiations that did not produce the desired products under batch conditions, such as the magnesiation of sensitive acrylic derivatives. The magnesiated species are subsequently quenched with various electrophiles, thereby introducing a broad range of functionalities. Go with the flow: Flow conditions allow a practical metalation of functionalized heterocycles and various acrylates in the presence of the base TMPMgCl·LiCl (TMP=2,2,6,6-tetramethylpiperidyl). More convenient temperatures and very fast reaction times can usually be achieved by applying the flow conditions. Sensitive acrylic derivatives can be magnesiated under flow conditions. Furthermore, the flow reactions are readily scalable without further optimization.

Substituted Spiro Compounds and Their Use for Producing Pain-Relief Medicaments

The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments.

Synthesis, rotamer orientation, and calcium channel modulation activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates

A group of racemic alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3- nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates (13a-q) was prepared using a modified Hantzsch reaction that involved the condensation of a 3- or 6-substituted-2-pyridinecarboxaldehyde (7a-j) with an alkyl or 2- phenethyl 3-aminocrotonate (11a-d) and nitroacetone (12). Nuclear Overhauser (NOE) studies indicated there is a significant rotamer fraction in solution where the pyridyl nitrogen is oriented above the 1,4-dihydropyridine ring, irrespective of whether a substituent is located at the 3- or 6-position. A potential H-bonding interaction between the pyridyl nitrogen free electron pair and the suitably positioned 1,4-dihydropyridine NH moiety may stablize this rotamer orientation. In vitro calcium channel antagonist and agonist activities were determined using guinea pig ileum longitudinal smooth muscle (GPILSM) and guinea pig left atrium (GPLA) assays, respectively. Compounds having an i-Pr ester substituent acted as dual cardioselective calcium channel agonists (GPLA)/smooth muscle-selective calcium channel antagonists (GPILSM), except for the C-4 3-nitro-2-pyridyl compound which exhibited an antagonist effect on both GPLA and GPILSM. In contrast, the compounds with a phenethyl ester group, which exhibited antagonist activity (IC50 = 10-5- 10-7 M range) on GPILSM, were devoid of cardiac agonist activity on GPLA. Structure-activity relationships showing the effect of a substituent (Me, CF3, C1, NO2, Ph) at the 3- or 6-position of a C-4 2-pyridyl moiety and a variety of ester substituents (Me, Et, i-Pr, PhCH2CH2-) upon calcium channel modulation are described. Compounds possessing a 3- or 6-substituted- 2-pyridyl moiety, in conjuction with an i-Pr ester substituent, are novel 1,4-dihydropyridine calcium channel modulators that offer a new drug design approach directed to the treatment of congestive heart failure and may also be useful as probes to study the structure-function relationships of calcium channels.